Preoperative Octreotide Treatment of Acromegaly

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate whether 6 months preoperative treatment with the somatostatin analogue octreotide improves the surgical outcome in patients with acromegaly.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Olavs Hospital
• Collaborator: Novartis
• Treatments: Octreotide

Criteria

Inclusion Criteria:

• GH nadir during a standard 75 g OGTT >= 5.0 mmol/L.

• Pituitary tumor by MRI-scan.

Exclusion Criteria:

• Immediate surgery indicated by usual clinical criteria.

• Pregnant.

• Known adverse effects of octreotide.

• Unfit for participation by any other reason.